This company listing is no longer active
Biotage (0GRP) Stock Overview
Provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
0GRP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biotage AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 142.95 |
| 52 Week High | SEK 201.40 |
| 52 Week Low | SEK 83.25 |
| Beta | 0.85 |
| 1 Month Change | 0.019% |
| 3 Month Change | 1.12% |
| 1 Year Change | -24.30% |
| 3 Year Change | -35.43% |
| 5 Year Change | -9.70% |
| Change since IPO | 1,479.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GRP | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0.2% | 12.0% | 0.08% |
| 1Y | -24.3% | 13.1% | 20.6% |
Return vs Industry: 0GRP underperformed the UK Life Sciences industry which returned 10.4% over the past year.
Return vs Market: 0GRP underperformed the UK Market which returned 6.7% over the past year.
Price Volatility
| 0GRP volatility | |
|---|---|
| 0GRP Average Weekly Movement | 0.5% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0GRP has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0GRP's weekly volatility has decreased from 10% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 622 | Frederic Vanderhaegen | www.biotage.com |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal and supported scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables, systems, and workflows; biomolecule purification solutions, including antibody, plasmid, AAV, and tagged proteins purification; automation systems; and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage AB (publ) Fundamentals Summary
| 0GRP fundamental statistics | |
|---|---|
| Market cap | SEK 11.46b |
| Earnings (TTM) | SEK 255.00m |
| Revenue (TTM) | SEK 1.96b |
Is 0GRP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GRP income statement (TTM) | |
|---|---|
| Revenue | SEK 1.96b |
| Cost of Revenue | SEK 733.00m |
| Gross Profit | SEK 1.23b |
| Other Expenses | SEK 973.00m |
| Earnings | SEK 255.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 06, 2025
| Earnings per share (EPS) | 3.19 |
| Gross Margin | 62.62% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 3.9% |
How did 0GRP perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/22 23:03 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotage AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |